100 related articles for article (PubMed ID: 26717470)
1. Prolactin: An Effective Partner for Anti-CD3 in Treating Type 1 Diabetes.
Xiao X
Endocrinology; 2016 Jan; 157(1):39-41. PubMed ID: 26717470
[No Abstract] [Full Text] [Related]
2. Prolactin as an Adjunct for Type 1 Diabetes Immunotherapy.
Hyslop CM; Tsai S; Shrivastava V; Santamaria P; Huang C
Endocrinology; 2016 Jan; 157(1):150-65. PubMed ID: 26512750
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD3 antibodies for type 1 diabetes: beyond expectations.
Bach JF
Lancet; 2011 Aug; 378(9790):459-60. PubMed ID: 21719098
[No Abstract] [Full Text] [Related]
4. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Herold KC; Gitelman SE; Masharani U; Hagopian W; Bisikirska B; Donaldson D; Rother K; Diamond B; Harlan DM; Bluestone JA
Diabetes; 2005 Jun; 54(6):1763-9. PubMed ID: 15919798
[TBL] [Abstract][Full Text] [Related]
5. The future of diabetes treatment.
Petersen JS
Ann Endocrinol (Paris); 2008 Apr; 69(2):166-7. PubMed ID: 18440491
[No Abstract] [Full Text] [Related]
6. The future is on the way: β cell function preservation for type 1 diabetes.
Yang J; Wei R
Med; 2024 Jan; 5(1):4-6. PubMed ID: 38218175
[TBL] [Abstract][Full Text] [Related]
7. Immuno-intervention and preservation of beta-cell function in type 1 diabetes.
Pozzilli P
Diabetes Metab Res Rev; 2007 May; 23(4):255-6. PubMed ID: 17476663
[No Abstract] [Full Text] [Related]
8. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC; Gitelman S; Greenbaum C; Puck J; Hagopian W; Gottlieb P; Sayre P; Bianchine P; Wong E; Seyfert-Margolis V; Bourcier K; Bluestone JA;
Clin Immunol; 2009 Aug; 132(2):166-73. PubMed ID: 19443276
[TBL] [Abstract][Full Text] [Related]
9. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?
Heine RJ; Diamant M; Mbanya JC; Nathan DM
BMJ; 2006 Dec; 333(7580):1200-4. PubMed ID: 17158386
[No Abstract] [Full Text] [Related]
10. Targeting innate immunity in type 1 diabetes: strike one.
Bonifacio E
Lancet; 2013 Jun; 381(9881):1880-1. PubMed ID: 23562091
[No Abstract] [Full Text] [Related]
11. Rituximab, B-lymphocyte depletion, and beta-cell function.
Nagafuchi S; Katsuta H; Anzai K
N Engl J Med; 2010 Feb; 362(8):761; author reply 761. PubMed ID: 20181981
[No Abstract] [Full Text] [Related]
12. Phytochemicals as modulators of β-cells and immunity for the therapy of type 1 diabetes: Recent discoveries in pharmacological mechanisms and clinical potential.
Apaya MK; Kuo TF; Yang MT; Yang G; Hsiao CL; Chang SB; Lin Y; Yang WC
Pharmacol Res; 2020 Jun; 156():104754. PubMed ID: 32173584
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD3 antibody MacroGenics Inc.
Brown WM
Curr Opin Investig Drugs; 2006 Apr; 7(4):381-8. PubMed ID: 16625825
[TBL] [Abstract][Full Text] [Related]
14. Vinegar decreases postprandial hyperglycemia in patients with type 1 diabetes.
Mitrou P; Raptis AE; Lambadiari V; Boutati E; Petsiou E; Spanoudi F; Papakonstantinou E; Maratou E; Economopoulos T; Dimitriadis G; Raptis SA
Diabetes Care; 2010 Feb; 33(2):e27. PubMed ID: 20103553
[No Abstract] [Full Text] [Related]
15. Studies assessing risk of treatments for diabetes mellitus and adverse pregnancy outcomes should control for known risk factors.
Edson-Heredia E; Rohwer RD; Wong M; Wang P; Vambergue A; Koivisto V
Diabetes Technol Ther; 2012 Dec; 14(12):1183-4; author reply 1185-6. PubMed ID: 23126581
[No Abstract] [Full Text] [Related]
16. Keeping cells alive. Can an old drug type give new life to transplants?
Curry A
Diabetes Forecast; 2013 Jul; 66(7):72-3. PubMed ID: 23866645
[No Abstract] [Full Text] [Related]
17. Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.
Xue S; Wasserfall C; Parker M; McGrail S; McGrail K; Campbell-Thompson M; Schatz DA; Atkinson MA; Haller MJ
J Diabetes Complications; 2010; 24(3):163-7. PubMed ID: 19217320
[TBL] [Abstract][Full Text] [Related]
18. [Fast-acting insulin analogs in the treatment of juvenile diabetes].
Tuominen JA; Karonen SL; Melamies L; Koivisto V
Duodecim; 1995; 111(3):232-6. PubMed ID: 8654285
[No Abstract] [Full Text] [Related]
19. New Medications for the Treatment of Diabetes.
Garg SK; Giordano D; Gallo T; Shah VN
Diabetes Technol Ther; 2017 Feb; 19(S1):S128-S140. PubMed ID: 28192022
[No Abstract] [Full Text] [Related]
20. Hypoglycaemia: costs, insulins and prevention.
Holt RI
Diabet Med; 2016 Apr; 33(4):419-20. PubMed ID: 26995756
[No Abstract] [Full Text] [Related]
[Next] [New Search]
